VIRALYTICS LTD
ONCOLYTIC VIRUSES

ASX and Media Release

US FDA pre-IND meeting update

25th June 2010, Sydney: Viralytics Limited (ASX: VLA, VLAO OTC: VRACY)

Viralytics was very pleased with the outcome of discussions that took place at the pre-Investigational New Drug ("pre-IND") meeting with the US Food & Drug Administration ("FDA") in Washington earlier this week.

The meeting followed the Company's submission of a comprehensive pre-IND data package to the FDA, setting out the Company's proposed Phase 2 clinical trials development path, and seeking clinical and regulatory guidance from the FDA.

The Company's Managing Director, Mr Bryan Dulhunty said, "Our dialogue with the FDA has been most productive and the FDA has provided Viralytics with guidance and recommendations to assist the Company in its preparation for filing of an Investigational New Drug ("IND") application which will allow us to commence our proposed Phase 2 clinical trial."

Viralytics will now work towards finalising its protocol design for its proposed Phase 2 clinical trial and preparation for filing an IND application.

Enquiries
Viralytics Ltd
Bryan Dulhunty
Managing Director

T: 02 9988 4000
M: 0433 217 876
E: bryan.dulhunty@viralytics.com
Website: www.viralytics.com

About Viralytics Ltd
Viralytics is listed on the Australian Securities Exchange (ASX code: VLA). Viralytics' ADR trades under VRACY on the OTC market in the USA. Viralytics' principal asset is the intellectual property relating to CAVATAK™, an Oncolytic Virus technology. CAVATAK™ is the trade name for Viralytics' proprietary formulation of the Coxsackievirus Type A21 (CVA21). CVA21 is a virus that occurs naturally in the community. CVA21 attaches to the outside of a cell, using a specific 'receptor' on the cell's surface (like a key fitting a lock). CVA21 uses two receptors to infect cells, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF). Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types, including: melanoma, prostate cancer, breast cancer, multiple myeloma and others.
